Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)

Inclusion Criteria: All of the following criteria must be met in order to be enrolled in the study:

• Age ≥18 years
• Life expectancy ≥6 months
• Participants with Common Terminology Criteria for Adverse Events (CTCAE) Grade 0 CIPN (exception, patients with multiple myeloma treated with bortezomib, CTCAE Grade <=1)
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
• Breast cancer only:
• Breast cancer beginning treatment with paclitaxel or docetaxel with curativeintent (i.e., not metastatic disease beyond regional lymph nodes)
• Planned minimum of 6 cycles of chemotherapy
• Lymphoma only:
• Incident lymphoma initiating treatment with vincristine
• Planned minimum of 4 cycles of chemotherapy
• Oxaliplatin-based regimens, Stage III colorectal cancer: Total of 6 months (plannedminimum of 12 cycles). May consider Stage IV with minimal metastatic confirmed withSponsor prior to enrollment
• Bortezomib use in untreated multiple myeloma: Total of 4 months (planned minimum of 9cycles)
• Written informed consent given
• Enrollment must be completed prior to receiving the first dose of chemotherapy

Exclusion Criteria: Patients meeting ANY of the following criteria are not eligible for participation:

• Evidence of central nervous system metastases
• Evidence of clinically significant peripheral neuropathy (CTCAE >2) as defined bypatient report of frequent numbness or tingling in the hands or feet
• Any uncontrolled serious illness or medical condition that would impact the conduct ofthe current study
• Previous exposure to neurotoxic chemotherapy drugs
• Pre-existing neurodegenerative disease (Parkinson's, Alzheimer's, Huntington's, etc.),neuromuscular disorder (multiple sclerosis, ALS, polio, hereditary neuromusculardisease) or history of stoke or history of traumatic brain injury
• General anesthesia less than one month prior to the first dose of neurotoxicchemotherapy